Perampanel (PER) is a first-in-class selective, non-competitive antagonist of the glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor that has demonstrated broad-spectrum anticonvulsant activity [1,2]. In Europe, once-daily PER is indicated for the adjunctive treatment of focal-onset seizures (FOS), including focal to bilateral tonic-clonic seizures (FBTCS), and for primary generalized tonic-clonic seizures in patients over 12 years of age [3].
7
FEB
FEB
0